
#60. Cracking the "Undruggable" Target
Episode 17
Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has been notoriously lethal, with few treatment options. Enter daraxonrasib (RMC-6236), a revolutionary "molecular glue" that targets the active "ON" state of mutated RAS proteins. In the recent Phase 3 RASolute 302 trial, this targeted therapy nearly doubled overall survival for metastatic pancreatic cancer patients compared to standard chemotherapy, extending it to 13.2 months. Join us as we explore the structural biology behind this tri-complex inhibitor, its unique resistance profile, and the future of precision cancer therapy. Produced by Dr. Jake Chen.
Publisher
Drug Discovery AI Talk
Link
podcasters.spotify.com/pod/show/jakechen/episodes/60--Cracking-the-Undruggable-Target-e3kdfsk
Published
June 6, 2026
Duration
21 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Dr. Jake Chen
Drug Discovery AI Talk
@drugdiscoveryaitalk
#cracking #undruggable #target
